FDA & EMA RWD Compliance In Obesity Trials: The Direct-To-Patient Action Plan

The landscape of obesity and GLP-1 research has reached a saturation point. With over 2,000 active studies vying for the same participants, the traditional site-based model is struggling to keep pace. Relying on manual data abstraction and decentralized clinical sites often leads to prohibitive costs, high error rates, and significant delays. To successfully scale to the 5,000-patient registries now required for long-term evidence, a shift in operational architecture is essential.

Modern research requires a Direct-to-Patient (DTP) approach that prioritizes high-fidelity data and regulatory-grade traceability. By leveraging automated EHR integration through frameworks like TEFCA, researchers can move beyond the "blind spots" of retrospective databases to build a prospective, longitudinal data stream. This model not only streamlines recruitment and identity verification but also ensures every data point is visually linked to its source, meeting the rigorous audit standards set by the FDA and EMA. Embracing this automated infrastructure allows for national scaling without the overhead of traditional site management, effectively cutting the total cost while maintaining the scientific integrity necessary for regulatory success.